4d Pharma Share Discussion Threads

[nigelpm] 24/6/2022 16:16

They can release the news whenever since all shares are suspended.

[mr roper] 24/6/2022 16:16

If the vaccines and 0518 are of interest to Merck’s it would be straightforward to arrange a placing at a premium with Merck as a strategic investor. They could take another 10% of the company for 25m. Just need to get the issuable ceiling sorted at the AGM.

Can honestly say this week has been one of the most spectacular Management kamikaze moments I’ve ever seen. Although not quite on a par with Asiamets Manini and Bird show it’s not far off.

[podium] 24/6/2022 16:13

I wonder if the pending announcement will come after hours, around 17:30. Sad thing is it is likely something that will completely shaft all current shareholders.

[nigelpm] 24/6/2022 16:11

As do I devonlad - 30p tops.

[devonlad] 24/6/2022 16:10

YasX, that is a fair point but the board would have known that and you would have thought would do anything to avoid it. They could have raised 40% at any point to to not do so would be beyond crazy, they have significant investments in this as Duncan said in the investor presentation and they stand to loose a lot more than anyone else. If they have breached and let the business breach then I think they are in a whole load of sheeeeiiiite! Gut feeling is this is a takeover, no idea on the price though.

[one_frankel] 24/6/2022 16:09

Ohh my, I wasnt even aware of those covenants from 2021 YasX but if that remains to be the case then its going to be incredibly disconcerting for investors here who'll end getting absolutely nothing for all their endeavours and is on a level par to utter contempt of investors.

[nigelpm] 24/6/2022 16:07

That's also interesting.

[nigelpm] 24/6/2022 16:07

Published: June 24, 2022 at 6:59 a.m. ET

Merck & Co. on Friday said the European Commission approved the expanded use of its blockbuster cancer drug Keytruda for certain patients with melanoma, the most serious form of skin cancer.

The Kenilworth, N.J., drugmaker said Keytruda is now approved as monotherapy for the treatment of people ages 12 and older with stage IIB or IIC melanoma and who have undergone complete resection.

Merck said the commission also approved expanding the indications for Keytruda in advanced melanoma and stage III melanoma, as adjuvant treatment following complete resection, to include adolescent patients ages 12 and up.

Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in dozens of indications around the world. Sales of the drug topped $17 billion last year.

[nigelpm] 24/6/2022 16:06

Quite touche - I';m going for US deal somewhere.

[touche] 24/6/2022 16:03

The piece that puzzles me is that we are suspended pending an announcement. Most suspensions come WITH an announcement as to why they are suspended.Add to this the exact timing release of the RNS, namely 1230 UK time and I see this as orchestrated.Feels to me suspension is to stop significant price moves on the NASDAQ today in case anything leaked, therefore expect news upon NASDAQ close is my guess as this likely involves a fairly large third-party

[nigelpm] 24/6/2022 16:03

They'd be utterly broken if someone had come in with a low ball bid also because of their inability to deliver.

[eeza] 24/6/2022 16:00

From the other site

"Coincidence?Today 15:56
Published: June 24, 2022 at 6:59 a.m. ET

Merck & Co. on Friday said the European Commission approved the expanded use of its blockbuster cancer drug Keytruda for certain patients with melanoma, the most serious form of skin cancer.

The Kenilworth, N.J., drugmaker said Keytruda is now approved as monotherapy for the treatment of people ages 12 and older with stage IIB or IIC melanoma and who have undergone complete resection.

Merck said the commission also approved expanding the indications for Keytruda in advanced melanoma and stage III melanoma, as adjuvant treatment following complete resection, to include adolescent patients ages 12 and up.

Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in dozens of indications around the world. Sales of the drug topped $17 billion last year."

[katsy] 24/6/2022 15:55

LAM in all sorts of trouble. Need cash or bust. Now they have an offer which is below the share price However they haven't suspended trading.

[nigelpm] 24/6/2022 15:51

Again - unlikely to be terminal otherwise would have probably announced immediately.

[yasx] 24/6/2022 15:51

My suspicion, though it is just a guess, is that it is related to this - if so, it is even more baffling as to why Duncan and Co. did not raise earlier...

On 29 July 2021, certain members of the Group entered into a loan and security agreement with Oxford Finance Luxembourg S.À R.L. and the loan is secured by substantially all of the assets of those members of the Group (including shares of certain subsidiaries in 4D pharma plc). The loan and security agreement and related security documentation contain customary representations and warranties and affirmative covenants and also contain certain restrictive covenants. The loan and security agreement also includes a financial covenant that requires
the Company to maintain a minimum amount of cash in bank accounts that are subject to a control agreement in favor of the lender if the Company does not achieve a certain equity raise threshold. The loan and security agreement also contains customary events of default. If we fail to comply with all such covenants, payments or other terms of the agreement, our lender could declare an event of default, which would give it the right to cancel any undrawn commitments and declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. In addition, our lender would have the right to proceed against the assets we provided as collateral pursuant to the loan and security agreement. If the debt under the loan and security agreement were accelerated, we may not have sufficient cash or be able to sell sufficient assets to repay this debt, which would harm our business and financial condition.

[pwal] 24/6/2022 15:51

So trading suspended for an announcement!

[nigelpm] 24/6/2022 15:48

The alternative is Oxford have had enough and called in their loan - quite possible also.

[nigelpm] 24/6/2022 15:47

perhaps I'm being overly optimistic but at £35m market cap I wouldn't be that surprised if someone simply comes in and puts them out of their misery - it's pocket change really at 25p offer.

[yasx] 24/6/2022 15:44

Further to my earlier post, it appeared that the only solution was an equity raise - but, even if the authority to do that is granted next week, given the current price, it may have been insufficient for them to trade as a solvent Co. for the next year. Are they going to announce that they conceded it is over, or is there another unknown out of nowhere. I still don't understand why they never raised in the past few months using the existing 40% authority - that really is perplexing.

I don't know, but watch with interest.

Good luck to holders - hope it works out for you.

[devonlad] 24/6/2022 15:39

Just a thought, they never progressed the Bavencio trial, I wonder if that was because of cash flow or because they already had a bid on the table from Merck and wanted to see how the funding issues progressed before starting it up?

[1airbag] 24/6/2022 15:35

If Merck liked the vaccine research they will buy 4D

[one_frankel] 24/6/2022 15:26

Nasdaq suspension is quoted as T1 which states that "trading is halted pending the release of material news"

...Now before many raise their expectations here just remember that material news is 'Any Type' of news which a company releases that might affect the value of its securities or influence investors' decisions.